Thrombosis Research
Volume 118, Issue 4 , Pages 447-453 , 2006

Effect of doxazosin gastrointestinal therapeutic system on platelet degranulation and platelet–leukocyte microaggregate formation induced by physiologic shear stress in hypertension

  • Manuel Labiós

      Affiliations

    • Flow Cytometry Unit, Clinical Pathology Department, La Fe University Hospital, Avda. Campanar 21, 46009 Valencia, Spain
    • ,
  • Marcial Martínez

      Affiliations

    • Hypertension Unit, Clinic Hospital, Valencia, Spain
    • Corresponding Author InformationCorresponding author. Fax: +34 96 1973089.
    • ,
  • Francisco Gabriel

      Affiliations

    • Flow Cytometry Unit, Clinical Pathology Department, La Fe University Hospital, Avda. Campanar 21, 46009 Valencia, Spain
    • ,
  • Victoria Guiral

      Affiliations

    • Hypertension Unit, Clinic Hospital, Valencia, Spain
    • ,
  • Justo Aznar

      Affiliations

    • Flow Cytometry Unit, Clinical Pathology Department, La Fe University Hospital, Avda. Campanar 21, 46009 Valencia, Spain

Received 28 April 2005 ,Revised 1 August 2005 ,Accepted 31 August 2005.

References 

  1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326:242–250
  2. Diodati JG, Cannon RO, Hussain N, Quyyumi AA. Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Am J Cardiol. 1995;75:443–448
  3. Blann AD, Nadar S, Lip GY. Pharmacological modulation of platelet function in hypertension. Hypertension. 2003;42:1–7
  4. Miyamoto S, Kawano H, Sakamoto T, Soejima H, Kajiwara I, Shimomura H, et al. Formation of platelet microaggregates correlates with adverse clinical outcome in patients with coronary artery disease. Thromb Haemost. 2003;89:681–686
  5. Labios M, Martinez M, Gabriel F, Gomez-Biedma S, Guiral V, Vivo M, et al. Flow cytometric analysis of platelet activation in hypertensive patients. Effect of doxazosin. Thromb Res. 2003;110:203–208
  6. Labios M, Martinez M, Gabriel F, Guiral V, Munoz A, Aznar J. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. Am J Hypertens. 2004;17:757–763
  7. Taylor MA, Ayers CR, Gear AR. Platelet calcium and quenched-flow aggregation kinetics in essential hypertension. Hypertension. 1989;13:558–566
  8. Martinez M, Vaya A, Labios M, Gabriel F, Guiral V, Aznar J. The effect of long-term treatment with hypotensive drugs on blood viscosity and erythrocyte deformability in patients with essential arterial hypertension. Clin Hemorheol Microcirc. 1997;17:193–198
  9. Toth K, Kesmarky G, Vekasi J, Nemes J, Czopf L, Kapronczay P, et al. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment. Clin Hemorheol Microcirc. 1999;21:209–216
  10. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, et al. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998;79:885–896
  11. do Ceu Monteiro M, Sansonetty F, Goncalves MJ, O'Connor JE. Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41. Cytometry. 1999;35:302–310
  12. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365–372
  13. Frangos SG, Gahtan V, Sumpio B. Localization of atherosclerosis: role of hemodynamics. Arch Surg. 1999;134:1142–1149
  14. Konstantopoulos K, Wu KK, Udden MM, Banez EI, Shattil SJ, Hellums JD. Flow cytometric studies of platelet responses to shear stress in whole blood. Biorheology. 1995;32:73–93
  15. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 1998;101:479–486
  16. Fredrickson BJ, Turner NA, Kleiman NS, Graziadei N, Maresh K, Mascelli MA, et al. Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation. 2000;101:1122–1129
  17. Li M, Goto S, Sakai H, Kim JY, Ichikawa N, Yoshida M, et al. Enhanced shear-induced von Willebrand factor binding to platelets in acute myocardial infarction. Thromb Res. 2000;100:251–261
  18. Nomura S, Nakamura T, Cone J, Tandon NN, Kambayashi J. Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation. Cytometry. 2000;40:173–181
  19. Holme PA, Orvim U, Hamers MJ, Solum NO, Brosstad FR, Barstad RM, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol. 1997;17:646–653
  20. Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 2001;158:277–287
  21. Bogar L. Hemorheology and hypertension: not “chicken or egg” but two chickens from similar eggs. Clin Hemorheol Microcirc. 2002;26:81–83
  22. Ciuffetti G, Pasqualini L, Pirro M, Lombardini R, De Sio M, Schillaci G, et al. Blood rheology in men with essential hypertension and capillary rarefaction. J Hum Hypertens. 2002;16:533–537
  23. Gagnet C, Devynck MA, Simon A, Levenson J. Influence of hypercholesterolemia and endothelin-3 pre-treatment on the effects of shear forces on platelet aggregation and cyclic GMP content. Atherosclerosis. 1999;143:91–97
  24. Yoshimura Y, Hiramatsu Y, Sato Y, Homma S, Enomoto Y, Kikuchi Y, et al. Activated neutrophils and platelet microaggregates impede blood filterability through microchannels during simulated extracorporeal circulation. Ann Thorac Surg. 2003;75:1254–1260
  25. Motulsky HJ, Insel PA. [3H]Dihydroergocryptine binding to alpha-adrenergic receptors of human platelets. A reassessment using the selective radioligands [3H]prazosin, [3H]yohimbine, and [3H]rauwolscine. Biochem Pharmacol. 1982;31:2591–2597
  26. Grant JA, Scrutton MC. Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation. Nature. 1979;277:659–661
  27. Hernandez Hernandez R, Carvajal A, Guerrero Pajuelo J, Armas de Hernandez M, Armas Padilla M, Barragan O, et al. The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: an in vitro study. Am Heart J. 1991;121:389–394
  28. Kim HJ, Lee G, Kim DH, Lee SJ, Yoon DK, Cho JH. Acute effects of serotonin on rat bladder contractility. Urol Int. 2002;68:44–48
  29. Khan MA, Thompson CS, Dashwood MR, Mumtaz FH, Mikhailidis DP, Morgan RJ. Doxazosin modifies serotonin-mediated rabbit urinary bladder contraction. Potential clinical relevance. Urol Res. 2000;28:116–121
  30. Jagroop IA, Mikhailidis DP. Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens. 2001;15:203–207

PII: S0049-3848(05)00381-6

doi: 10.1016/j.thromres.2005.08.012

Thrombosis Research
Volume 118, Issue 4 , Pages 447-453 , 2006

Article Tools